Olumiant® (Baricitinib)

Para consultar la información para prescribir completa de Olumiant® (Baricitinib) de clic en el siguiente enlace: Información para prescribir

La información es proporcionada en respuesta a su solicitud, y puede contener datos relacionados a dosis, usos, formulaciones y poblaciones diferentes a la Información para Prescribir del producto. Consulte la Información para Prescribir en la liga que aparece arriba.

Baricitinib: Cardiovascular Risk

Los pacientes con artritis reumatoide (AR) tienen un mayor riesgo cardiovascular (CV) en función de su AR.

Baricitinib and Cardiovascular Risk

Patients with RA have an increased CV risk based on their RA.1

Cardiovascular risk was evaluated in the BARI phase 3 RA clinical program using the FRS and RRS.2

Framingham Risk Score Results

The FRS represents the likelihood of an individual patient experiencing a CVD event in the next 10 years. It is calculated for men and women aged ≥30 and ≤74 years with no prior history of CVD.2

There were no consistent statistically significant within-group changes from baseline in FRS or statistically significant differences between the BARI 4 mg and placebo groups.2

Reynolds Risk Score Results

The RRS is an alternative to the FRS for characterization of CV risk in non-diabetic men and women aged ≥45 and ≤80 years with no prior history of CVD and/or cerebrovascular events and also represents the likelihood of an individual patient experiencing a CVD event in the next 10 years.2

  • There was a statistically significant within-group decrease in RRS for BARI 4 mg and placebo, with no statistically significant difference between treatment groups in any study, except for one study, RA-BEAM, where there were statistically significantly larger decreases in BARI 4 mg compared to placebo.2

  • Similar findings applied to non-diabetic patients aged 45 to 80 with no prior CVD (regardless of hsCRP status) and the subgroup of non-diabetic patients aged 45 to 80 with no prior CVD and baseline hsCRP ≤20 mg/L, except for RA-BEAM, where there is no significant within-group decrease in RRS for placebo group.2

References

1. Kume K, Amano K, Yamada S. AB0463 Tofacitinib improves arterial stiffness with methotrexate-resistant active rheumatoid arthritis: a cohort study [abstract]. Ann Rheum Dis. 2014;73(suppl 2):961. http://dx.doi.org/10.1136/annrheumdis-2014-eular.1019

2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Glossary

BARI = baricitinib

CV = cardiovascular

CVD = cardiovascular disease

FRS = Framingham Risk Score

hsCRP = high-sensitivity C-reactive protein

RA = rheumatoid arthritis

RRS = Reynolds Risk Score

Fecha de la última revisión: 2019 M07 15


Contáctenos para saber más de la información Médica de Lilly

Contacto vía correo electrónico

Correo electrónico: infomed@lilly.com

Envíe su consulta

Escriba su consulta